PHDs inhibitor DMOG promotes the vascularization process in the AV loop by HIF-1a up-regulation and the preliminary discussion on its kinetics in rat

BMC Biotechnology

Quan Yuan³  Oliver Bleiziffer²  Anja M Boos²  Jiaming Sun³  Andreas Brandl²  Justus P Beier²  Andreas Arkudas²  Marweh Schmitz²  Ulrich Kneser¹  Raymund E Horch² 

[1] Department of Hand, Plastic and Reconstructive Surgery, Burn Care Unit, BG-Trauma Centre Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany

[2] Department of Plastic and Hand Surgery, University Hospital of Erlangen, Friedrich Alexander University, Erlangen Nuernberg, (FAU), Germany

[3] Department of Plastic Surgery, Union Hospital, Huazhong University of Science and Technology, Wuhan, China

关键词: Kinetics;    Dimethyloxallyl Glycine;    PHD inhibitor;    Arteriovenous loop;    Vasculorization;    Hypoxia;   

Others  :  1121342
DOI  :  10.1186/s12896-014-0112-x

 received in 2014-02-08, accepted in 2014-12-16,  发布年份 2014

【 摘 要 】

Background

The Arterovenous Loop (AV Loop) model is a vascularization model in tissue engineering research, which is capable of generating a three dimensional in vivo unit with cells as well as the supporting vessels within an isolation chmaber. In our previous studies the AV loop in the isolation chamber was discovered to undergo hypoxia, characterized by Hypoxia Inducible Factor (HIF) up-regulation. The vascularization followed the increase of HIF-α temporally, while it was spatially positively correlated with the HIF-α level, as well. This study aims to prove that HIF-1a up-regulation is the stimulus for vascularization in the AV loop model.

Method

The AV loop model in rats was created by interposing a femoral vein graft into the distal ends of the contralateral femoral artery and vein, and the loop was embeded in fibrin matrix and fixed in isolation chamber. PHD (prolyl hydroxylases) inhibitor DMOG (Dimethyloxallyl Glycine) was applied systemically in the rats in 40 mg/KG at day 0 and day 3 (DMOG-1), or in 15 mg/KG at day 8, day10 and day12 (DMOG-2). Two weeks later the specimens were explanted and underwent morphological and molecular evaluations.

Results

Compared to the control group, in the DMOG-2 group the HIF-1α positive rate was siginicantly raised as shown in immunohistochemistry staining, accompanied with a smaller cross section area and greater vessel density, and a HIF-1α accumulation in the kidney. The mRNA of HIF-1α and its angiogenic target gene all increased in different extends. Ki67 IHC demostrate more positive cells. There were no significant change in the DMOG-1 group.

Conclusion

By applying DMOG systemically, HIF-1α was up-regulated at the protein level and at the mRNA level, acompanied with angiogenic target gene up-regulateion, and the vascularization was promoted correspondingly. DMOG given at lower dosage constantly after one week tends to have better effect than the group given at larger dosage in the early stage in this model, and promotes cell proliferation, as evidenced by Ki67 IHC. Thus, this study proves that HIF-1a up-regulation is the stimulus for vascularization in the AV loop model and that the process of the vessel outgrowth can be controlled in the AV Loop model utilizing this mechanism.

【 授权许可】

   
2014 Quan et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Novosel EC, Kleinhans C, Kluger PJ: Vascularization is the key challenge in tissue engineering. Adv Drug Deliv Rev 2011, 63(4–5):300-311.
• [2]Jain RK, Au P, Tam J, Duda DG, Fukumura D: Engineering vascularized tissue. Nat Biotechnol 2005, 23(7):821-823.
• [3]Bleiziffer O, Hammon M, Arkudas A, Taeger CD, Beier JP, Amann K, Naschberger E, Stürzl M, Horch RE, Kneser U: Guanylate-binding protein 1 expression from embryonal endothelial progenitor cells reduces blood vessel density and cellular apoptosis in an axially vascularised tissue-engineered construct. BMC Biotechnol 2012, 12:94. BioMed Central Full Text
• [4]Erol OO, Spira M: New capillary bed formation with a surgically constructed arteriovenous fistula. Surg Forum 1979, 30:530-531.
• [5]Polykandriotis E, Arkudas A, Horch RE, Stürzl M, Kneser U: Autonomously vascularized cellular constructs in tissue engineering: opening a new perspective for biomedical science. J Cell Mol Med 2007, 11:6-20.
• [6]Lokmic Z, Stillaert F, Morrison WA, Thompson EW, Mitchell GM: An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct. FASEB J 2007, 21(2):511-522.
• [7]Kneser U, Polykandriotis E, Ohnolz J, Heidner K, Grabinger L, Euler S, Amann KU, Hess A, Brune K, Greil P, Stürzl M, Horch RE: Engineering of vascularized transplantable bone tissues: induction of axial vascularization in an osteoconductive matrix using an arteriovenous loop. Tissue Eng 2006, 12(7):1721-1731.
• [8]Beier JP, Hess A, Loew J, Heinrich J, Boos AM, Arkudas A, Polykandriotis E, Bleiziffer O, Horch RE, Kneser U: De novo generation of an axially vascularized processed bovine cancellous-bone substitute in the sheep arteriovenous-loop model. Eur Surg Res 2011, 46(3):148-155.
• [9]Brown DL, Meagher PJ, Knight KR, Keramidaris E, Romeo-Meeuw R, Penington AJ, Morrison WA: Survival and function of transplanted islet cells on an in vivo, vascularized tissue engineering platform in the rat: A pilot study. Cell Transplant 2006, 15(4):319-324.
• [10]Borschel GH, Dow DE, Dennis RG, Brown DL: Tissue-engineered axially vascularized contractile skeletal muscle. Plast Reconstr Surg 2006, 117(7):2235-2242.
• [11]Manasseri B, Cuccia G, Moimas S, D'Alcontres FS, Polito F, Bitto A, Altavilla D, Squadrito F, Geuna S, Pattarini L, Zentilin L, Collesi C, Puligadda U, Giacca M, Colonna MR: Microsurgical arterovenous loops and biological templates: a novel in vivo chamber for tissue engineering. Microsurgery 2007, 27(7):623-629.
• [12]Horch RE, Boos AM, Quan Y, Bleiziffer O, Detsch R, Boccaccini AR, Alexiou C, Sun J, Beier JP, Arkudas A: Cancer research by means of tissue engineering - is there a rationale? J Cell Mol Med 2013, 17(10):1197-1206.
• [13]Rath SN, Strobel LA, Arkudas A, Beier JP, Maier AK, Greil P, Horch RE, Kneser U: Osteoinduction and survival of osteoblasts and bone-marrow stromal cells in 3D biphasic calcium phosphate scaffolds under static and dynamic culture conditions. J Cell Mol Med 2012, 16(10):2350-2361.
• [14]Horch RE, Kneser U, Polykandriotis E, Schmidt VJ, Sun J, Arkudas A: Tissue engineering and regenerative medicine -where do we stand? J Cell Mol Med 2012, 16(6):1157-1165.
• [15]Polykandriotis E, Schmidt VJ, Kneser U, Jianming S, Boccaccini AR, Horch RE: [Bioreactors in regenerative medicine--from a technical device to a reconstructive alternative?]. Handchir Mikrochir Plast Chi 2012, 44(4):198-203.
• [16]Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9(6):677-684.
• [17]Leffler M, Derrick KL, McNulty A, Malsiner C, Dragu A, Horch RE: Changes of anabolic processes at the cellular and molecular level in chronic wounds under topical negative pressure can be revealed by transcriptome analysis. J Cell Mol Med 2011, 15(7):1564-1571.
• [18]Malsiner CC, Schmitz M, Horch RE, Keller AK, Leffler M: Vessel transformation in chronic wounds under topical negative pressure therapy: an immunohistochemical analysis.Int Wound J 2013. Sep 13. doi:10.1111/iwj.12143. [Epub ahead of print].
• [19]Gu YZ, Hogenesch JB, Bradfield CA: The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 2000, 40:519-561.
• [20]Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16(9):4604-4613.
• [21]Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G: Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 2006, 107(7):2705-2712.
• [22]Weidemann A, Johnson RS: Biology of HIF-1alpha. Cell Death Differ 2008, 15(4):621-627.
• [23]Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294(5545):1337-1340.
• [24]Nagel S, Papadakis M,Chen R,Hoyte LC,Brooks KJ, Gallichan D, Sibson NR, Pugh C, Buchan AM: Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats.J Cereb Blood Flow Metab. 31(1):132–143.
• [25]Gelse K, Pfander D, Obier S, Knaup KX, Wiesener M, Hennig FF, Swoboda B: Role of hypoxia-inducible factor 1 alpha in the integrity of articular cartilage in murine knee joints. Arthritis Res Ther 2008, 10:R111. BioMed Central Full Text
• [26]Lim CS, Qiao X, Reslan OM, Xia Y, Raffetto JD, Paleolog E, Davies AH, Khalil RA: Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg 2011, 53(3):764-773.
• [27]Song YR, You SJ, Lee YM, Chin HJ, Chae DW, Oh YK, Joo KW, Han JS, Na KY: Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant 2010, 25(1):77-85.
• [28]Pajusola K, Künnapuu J, Vuorikoski S, Soronen J, André H, Pereira T, Korpisalo P, Ylä-Herttuala S, Poellinger L, Alitalo K: Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 2005, 19(10):1365-1367.
• [29]Dragu A, Kleinmann JA, Taeger CD, Birkholz T, Schmidt J, Geppert CI, Präbst K, Unglaub F, Münch F, Weyand M, Kneser U, Horch RE: Immunohistochemical evaluation after ex vivo perfusion of rectus abdominis muscle flaps in a porcine model. Plast Reconstr Surg 2012, 130(2):265e-273e.
• [30]Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182(3):311-322.
• [31]Fong GH: Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 2008, 11(2):121-140.
• [32]Warnecke C, Griethe W, Weidemann A, Jürgensen JS, Willam C, Bachmann S, Ivashchenko Y, Wagner I, Frei U, Wiesener M, Eckardt KU: Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 2003, 17(9):1186-1188.
• [33]Breen A, O’Brien T, Pandit A: Fibrin as a delivery system for therapeutic drugs and biomolecules. Tissue Eng Part B Rev 2009, 15(2):201-214.
• [34]Arkudas A, Tjiawi J, Bleiziffer O, Grabinger L, Polykandriotis E, Beier JP, Stürzl M, Horch RE, Kneser U: Fibrin gel-immobilized VEGF and bFGF efficiently stimulate angiogenesis in the AV loop model. Mol Med 2007, 13(9-10):480-487.
• [35]Bleiziffer O, Hammon M, Naschberger E, Lipnik K, Arkudas A, Rath S, Pryymachuk G, Beier JP, Stürzl M, Horch RE, Kneser U: Endothelial Progenitor Cells contribute to formation of capillaries and alter fibrocascular tissue after subcutaneous implantation in a fibrin matrix. J Cell Mol Med 2010, 15(11):2452-2461.
• [36]Hentze MW, Muckenthaler MU, Andrews NC: Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117(3):285-297.